IN2012DN02693A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN02693A IN2012DN02693A IN2693DEN2012A IN2012DN02693A IN 2012DN02693 A IN2012DN02693 A IN 2012DN02693A IN 2693DEN2012 A IN2693DEN2012 A IN 2693DEN2012A IN 2012DN02693 A IN2012DN02693 A IN 2012DN02693A
- Authority
- IN
- India
- Prior art keywords
- methods
- subject compound
- treating
- compositions
- xii
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 2
- 208000019425 cirrhosis of liver Diseases 0.000 abstract 1
- 208000010710 hepatitis C virus infection Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24646509P | 2009-09-28 | 2009-09-28 | |
| US32425110P | 2010-04-14 | 2010-04-14 | |
| US34573710P | 2010-05-18 | 2010-05-18 | |
| US34623810P | 2010-05-19 | 2010-05-19 | |
| PCT/US2010/050298 WO2011038293A1 (en) | 2009-09-28 | 2010-09-24 | Cyclic peptide inhibitors of hepatitis c virus replication |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012DN02693A true IN2012DN02693A (enExample) | 2015-09-04 |
Family
ID=43796242
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2693DEN2012 IN2012DN02693A (enExample) | 2009-09-28 | 2010-09-24 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20110081315A1 (enExample) |
| EP (1) | EP2483290A4 (enExample) |
| JP (1) | JP2013505952A (enExample) |
| KR (1) | KR20130026410A (enExample) |
| CN (2) | CN102741270B (enExample) |
| AR (1) | AR078462A1 (enExample) |
| AU (1) | AU2010298028A1 (enExample) |
| CA (1) | CA2775697A1 (enExample) |
| CO (1) | CO6531497A2 (enExample) |
| EA (1) | EA201290128A1 (enExample) |
| EC (1) | ECSP12011845A (enExample) |
| IL (1) | IL218766A0 (enExample) |
| IN (1) | IN2012DN02693A (enExample) |
| MA (1) | MA33720B1 (enExample) |
| MX (1) | MX2012003500A (enExample) |
| PH (1) | PH12012500602A1 (enExample) |
| TN (1) | TN2012000135A1 (enExample) |
| TW (1) | TW201124137A (enExample) |
| WO (1) | WO2011038293A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2305696A3 (en) * | 2005-07-25 | 2011-10-12 | Intermune, Inc. | Macrocyclic inhibitors of Hepatitis C virus replication |
| JP2009511595A (ja) * | 2005-10-11 | 2009-03-19 | インターミューン・インコーポレーテッド | Ｃ型肝炎ウイルスの複製を阻害する化合物および方法 |
| EP2282762A2 (en) * | 2008-04-15 | 2011-02-16 | Intermune, Inc. | Novel macrocyclic inhibitors of hepatitis c virus replication |
| CA2740728A1 (en) * | 2008-10-15 | 2010-04-22 | Intermune, Inc. | Therapeutic antiviral peptides |
| WO2011041551A1 (en) * | 2009-10-01 | 2011-04-07 | Intermune, Inc. | Therapeutic antiviral peptides |
| US9181233B2 (en) * | 2010-03-03 | 2015-11-10 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| TW201211046A (en) * | 2010-06-07 | 2012-03-16 | Enanta Pharm Inc | Macrocyclic hepatitis C serine protease inhibitors |
| CA2811025C (en) * | 2010-09-10 | 2018-07-17 | Shionogi & Co., Ltd. | Hetero ring-fused imidazole derivative having ampk activating effect |
| US20120101032A1 (en) * | 2010-10-22 | 2012-04-26 | Intermune, Inc. | Novel macrocyclic inhibitors of hepatitis c virus replication |
| US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8691757B2 (en) | 2011-06-15 | 2014-04-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| MX356686B (es) * | 2011-09-22 | 2018-06-07 | Janssen Pharmaceuticals Inc | Procesos e intermediarios para la preparación de un inhibidor macrocíclico de la proteasa del virus de la hepatitis c. |
| JP2015525223A (ja) | 2012-06-14 | 2015-09-03 | ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ | 動物有害生物を駆除するための置換３−ピリジルチアゾール化合物および誘導体を使用する有害生物防除方法 |
| UA119315C2 (uk) | 2012-07-03 | 2019-06-10 | Гіліад Фармассет Елелсі | Інгібітори вірусу гепатиту с |
| US9499550B2 (en) | 2012-10-19 | 2016-11-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2014071007A1 (en) | 2012-11-02 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| WO2014070964A1 (en) | 2012-11-02 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| US9409943B2 (en) | 2012-11-05 | 2016-08-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| JP6342922B2 (ja) | 2013-03-07 | 2018-06-13 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｃ型肝炎ウイルス阻害剤 |
| JP2016512219A (ja) * | 2013-03-15 | 2016-04-25 | シンジェンタ パーティシペーションズ アーゲー | 殺菌活性のあるイミダゾピリジン誘導体 |
| MX2015013224A (es) | 2013-03-15 | 2015-12-11 | Gilead Sciences Inc | Inhibidores macrociclicos y biciclicos del virus de la hepatitis c. |
| CN105884779B (zh) * | 2015-02-13 | 2018-06-12 | 广东东阳光药业有限公司 | 作为丙型肝炎抑制剂的化合物及其在药物中的应用 |
| CN108314648A (zh) * | 2018-04-12 | 2018-07-24 | 苏州康润医药有限公司 | 4-溴-7-氟异喹啉的合成方法 |
| CN110305018B (zh) * | 2019-06-06 | 2022-07-15 | 浙江普洛家园药业有限公司 | 一种3-溴-2-氟硝基苯的制备方法 |
| CN112358447B (zh) * | 2020-11-16 | 2022-04-12 | 苏州康润医药有限公司 | 7-氟异喹啉-1-羧酸的合成方法 |
| CN114105800B (zh) * | 2021-11-25 | 2023-09-01 | 杭州国瑞生物科技有限公司 | 一种2,3-二氨基苯甲酸甲酯的制备方法 |
| WO2025257072A1 (en) * | 2024-06-14 | 2025-12-18 | Syngenta Crop Protection Ag | Pesticidally active 2-oxobenzimidazole compounds |
| CN119143611A (zh) * | 2024-11-15 | 2024-12-17 | 浙江大学衢州研究院 | 一种n-异丙基对氟苯胺的连续制备方法 |
Family Cites Families (120)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3547119A (en) | 1967-12-08 | 1970-12-15 | Baxter Laboratories Inc | Catheter assembly |
| US3798209A (en) * | 1971-06-01 | 1974-03-19 | Icn Pharmaceuticals | 1,2,4-triazole nucleosides |
| US4211771A (en) | 1971-06-01 | 1980-07-08 | Robins Ronald K | Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide |
| US4311137A (en) | 1980-04-30 | 1982-01-19 | Sherwood Medical Industries Inc. | Infusion device |
| US4531937A (en) | 1983-01-24 | 1985-07-30 | Pacesetter Systems, Inc. | Introducer catheter apparatus and method of use |
| CS263951B1 (en) * | 1985-04-25 | 1989-05-12 | Antonin Holy | 9-(phosponylmethoxyalkyl)adenines and method of their preparation |
| US4755173A (en) | 1986-02-25 | 1988-07-05 | Pacesetter Infusion, Ltd. | Soft cannula subcutaneous injection set |
| US5354866A (en) | 1989-05-23 | 1994-10-11 | Abbott Laboratories | Retroviral protease inhibiting compounds |
| US5696270A (en) | 1989-05-23 | 1997-12-09 | Abbott Laboratories | Intermediate for making retroviral protease inhibiting compounds |
| GB8918806D0 (en) * | 1989-08-17 | 1989-09-27 | Shell Int Research | Chiral compounds,their preparation and use |
| US5716632A (en) | 1989-11-22 | 1998-02-10 | Margolin; Solomon B. | Compositions and methods for reparation and prevention of fibrotic lesions |
| US5310562A (en) | 1989-11-22 | 1994-05-10 | Margolin Solomon B | Composition and method for reparation and prevention of fibrotic lesions |
| US5518729A (en) | 1989-11-22 | 1996-05-21 | Margolin; Solomon B. | Compositions and methods for reparation and prevention of fibrotic lesions |
| EP1302468B1 (en) | 1992-12-29 | 2008-12-17 | Abbott Laboratories | Processes and intermediates for manufacturing retroviral protease inhibiting compounds |
| US5545143A (en) | 1993-01-21 | 1996-08-13 | T. S. I. Medical | Device for subcutaneous medication delivery |
| US5624949A (en) * | 1993-12-07 | 1997-04-29 | Eli Lilly And Company | Protein kinase C inhibitors |
| US6693072B2 (en) * | 1994-06-02 | 2004-02-17 | Aventis Pharmaceuticals Inc. | Elastase inhibitors |
| US5756466A (en) * | 1994-06-17 | 1998-05-26 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1β converting enzyme |
| US6090822A (en) | 1995-03-03 | 2000-07-18 | Margolin; Solomon B. | Treatment of cytokine growth factor caused disorders |
| US6232333B1 (en) | 1996-11-21 | 2001-05-15 | Abbott Laboratories | Pharmaceutical composition |
| US6323180B1 (en) * | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
| US6277830B1 (en) | 1998-10-16 | 2001-08-21 | Schering Corporation | 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon |
| US6608027B1 (en) * | 1999-04-06 | 2003-08-19 | Boehringer Ingelheim (Canada) Ltd | Macrocyclic peptides active against the hepatitis C virus |
| US7256005B2 (en) | 1999-08-10 | 2007-08-14 | The Chancellor, Masters And Scholars Of The University Of Oxford | Methods for identifying iminosugar derivatives that inhibit HCV p7 ion channel activity |
| DE60137207D1 (de) * | 2000-04-05 | 2009-02-12 | Schering Corp | Makrozyklische inhibitoren der ns3-serinprotease des hepatitis c-virus mit stickstoffhaltigen zyklischen p2-gruppen |
| KR20020097220A (ko) * | 2000-04-19 | 2002-12-31 | 쉐링 코포레이션 | 알킬 및 아릴 알라닌 ｐ2 잔기를 포함하는 ｃ형 간염바이러스의 매크로사이클릭 ｎｓ3-세린 프로테아제 억제제 |
| MY139078A (en) * | 2000-07-21 | 2009-08-28 | Schering Corp | Peptides as ns3-serine protease inhibitors of hepatitis c virus |
| US7244721B2 (en) * | 2000-07-21 | 2007-07-17 | Schering Corporation | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
| US6872805B2 (en) * | 2000-11-20 | 2005-03-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2002089738A2 (en) * | 2001-05-08 | 2002-11-14 | Yale University | Proteomimetic compounds and methods |
| US6867185B2 (en) * | 2001-12-20 | 2005-03-15 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
| NZ575692A (en) * | 2002-04-11 | 2009-10-30 | Vertex Pharma | Inhibitors of Serine Proteases, Particularly Hepatitis C Virus NS3-NS4 Protease |
| MY140680A (en) * | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| ES2350201T3 (es) * | 2002-05-20 | 2011-01-20 | Bristol-Myers Squibb Company | Sulfamidas heterocíclicas como inhibidores del virus de la hepatitis c. |
| AU2003299519A1 (en) * | 2002-05-20 | 2004-05-04 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| ES2315568T3 (es) * | 2002-05-20 | 2009-04-01 | Bristol-Myers Squibb Company | Inhibidores del virus de la hepatitis c basados en cicloalquilo p1' sustituido. |
| PL199412B1 (pl) * | 2002-10-15 | 2008-09-30 | Boehringer Ingelheim Int | Nowe kompleksy rutenu jako (pre)katalizatory reakcji metatezy, pochodne 2-alkoksy-5-nitrostyrenu jako związki pośrednie i sposób ich wytwarzania |
| JP4231524B2 (ja) * | 2003-04-10 | 2009-03-04 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 大環状化合物の製造方法 |
| TW200510391A (en) * | 2003-04-11 | 2005-03-16 | Vertex Pharma | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
| DE602004019518D1 (de) * | 2003-04-16 | 2009-04-02 | Bristol Myers Squibb Co | Makrocyclische isochinolinpeptidinhibitoren des hepatitis-c-virus |
| DE602004023924D1 (en) * | 2003-04-18 | 2009-12-17 | Enanta Pharm Inc | Ease-hemmer |
| US7125845B2 (en) * | 2003-07-03 | 2006-10-24 | Enanta Pharmaceuticals, Inc. | Aza-peptide macrocyclic hepatitis C serine protease inhibitors |
| AU2004282148A1 (en) * | 2003-10-10 | 2005-04-28 | Vertex Pharmaceuticals Incoporated | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
| US7491794B2 (en) * | 2003-10-14 | 2009-02-17 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
| CN103145715B (zh) * | 2003-10-14 | 2016-08-03 | F·霍夫曼-罗须公司 | 作为hcv复制抑制剂的巨环羧酸和酰基磺酰胺 |
| US7939538B2 (en) * | 2004-06-28 | 2011-05-10 | Amgen Inc. | Compounds, compositions and methods for prevention and treatment of inflammatory and immunoregulatory disorders and diseases |
| DE102004033312A1 (de) * | 2004-07-08 | 2006-01-26 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Kontinuierliches Metatheseverfahren mit Ruthenium-Katalysatoren |
| WO2006007708A1 (en) * | 2004-07-20 | 2006-01-26 | Boehringer Engelheim International Gmbh | Hepatitis c inhibitor peptide analogs |
| MX2007002371A (es) * | 2004-08-27 | 2007-04-23 | Schering Corp | Compuestos de acilsulfonamida como inhibidores de la serina proteasa ns3 del virus de la hepatitis c. |
| US7189844B2 (en) * | 2004-09-17 | 2007-03-13 | Boehringer Ingelheim International Gmbh | Ring-closing metathesis process in supercritical fluid |
| JP4705164B2 (ja) * | 2005-05-02 | 2011-06-22 | メルク・シャープ・エンド・ドーム・コーポレイション | Ｈｃｖｎｓ３プロテアーゼ阻害剤 |
| US7608592B2 (en) * | 2005-06-30 | 2009-10-27 | Virobay, Inc. | HCV inhibitors |
| US7601686B2 (en) * | 2005-07-11 | 2009-10-13 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| TWI389908B (zh) * | 2005-07-14 | 2013-03-21 | Gilead Sciences Inc | 抗病毒化合物類 |
| TWI387603B (zh) * | 2005-07-20 | 2013-03-01 | Merck Sharp & Dohme | Ｈｃｖ ｎｓ３蛋白酶抑制劑 |
| EP2305696A3 (en) | 2005-07-25 | 2011-10-12 | Intermune, Inc. | Macrocyclic inhibitors of Hepatitis C virus replication |
| PE20070211A1 (es) * | 2005-07-29 | 2007-05-12 | Medivir Ab | Compuestos macrociclicos como inhibidores del virus de hepatitis c |
| ATE524475T1 (de) * | 2005-07-29 | 2011-09-15 | Tibotec Pharm Ltd | Makrocyclische inhibitoren des hepatitis-c-virus |
| EP2402331A1 (en) * | 2005-08-02 | 2012-01-04 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
| JP2009511595A (ja) * | 2005-10-11 | 2009-03-19 | インターミューン・インコーポレーテッド | Ｃ型肝炎ウイルスの複製を阻害する化合物および方法 |
| US7772183B2 (en) * | 2005-10-12 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2007057317A1 (en) * | 2005-11-16 | 2007-05-24 | F. Hoffmann-La Roche Ag | Novel pyrrolidine derivatives as inhibitors of coagulation factor xa |
| US7728148B2 (en) * | 2006-06-06 | 2010-06-01 | Enanta Pharmaceuticals, Inc. | Acyclic oximyl hepatitis C protease inhibitors |
| KR20090024834A (ko) * | 2006-07-05 | 2009-03-09 | 인터뮨, 인크. | Ｃ형 간염 바이러스 복제의 신규 억제제 |
| EP2049474B1 (en) * | 2006-07-11 | 2015-11-04 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| US7906619B2 (en) * | 2006-07-13 | 2011-03-15 | Achillion Pharmaceuticals, Inc. | 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication |
| US7718612B2 (en) * | 2007-08-02 | 2010-05-18 | Enanta Pharmaceuticals, Inc. | Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors |
| US7635683B2 (en) * | 2006-08-04 | 2009-12-22 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl tripeptide hepatitis C virus inhibitors |
| CA2656816A1 (en) * | 2006-08-04 | 2008-02-14 | Enanta Pharmaceuticals, Inc. | Tetrazolyl macrocyclic hepatitis c serine protease inhibitors |
| US20090035267A1 (en) * | 2007-07-31 | 2009-02-05 | Moore Joel D | Acyclic, pyridazinone-derived hepatitis c serine protease inhibitors |
| US7582605B2 (en) * | 2006-08-11 | 2009-09-01 | Enanta Pharmaceuticals, Inc. | Phosphorus-containing hepatitis C serine protease inhibitors |
| US7662779B2 (en) * | 2006-08-11 | 2010-02-16 | Enanta Pharmaceuticals, Inc. | Triazolyl macrocyclic hepatitis C serine protease inhibitors |
| US20090098085A1 (en) * | 2006-08-11 | 2009-04-16 | Ying Sun | Tetrazolyl acyclic hepatitis c serine protease inhibitors |
| US20090035268A1 (en) * | 2007-08-01 | 2009-02-05 | Ying Sun | Tetrazolyl acyclic hepatitis c serine protease inhibitors |
| US7687459B2 (en) * | 2006-08-11 | 2010-03-30 | Enanta Pharmaceuticals, Inc. | Arylalkoxyl hepatitis C virus protease inhibitors |
| US7605126B2 (en) * | 2006-08-11 | 2009-10-20 | Enanta Pharmaceuticals, Inc. | Acylaminoheteroaryl hepatitis C virus protease inhibitors |
| US20080038225A1 (en) * | 2006-08-11 | 2008-02-14 | Ying Sun | Triazolyl acyclic hepatitis c serine protease inhibitors |
| US20080107625A1 (en) * | 2006-11-01 | 2008-05-08 | Bristol-Myers Squibb Company | Inhibitors of Hepatitis C Virus |
| US8343477B2 (en) * | 2006-11-01 | 2013-01-01 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
| US7772180B2 (en) * | 2006-11-09 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| MX2009005219A (es) * | 2006-11-17 | 2009-05-27 | Tibotec Pharm Ltd | Inhibidores macrociclicos del virus de hepatitis c. |
| US20100087382A1 (en) * | 2007-02-16 | 2010-04-08 | Boehringer Ingelheim International Gmbh | Inhibitors of Hepatitis C NS3 Protease |
| MX2009010205A (es) * | 2007-03-23 | 2009-10-19 | Schering Corp | Inhibidores de cetoamida p1-no epimerizables de proteasa ns3 de virus de hepatitis c. |
| US20090123423A1 (en) * | 2007-04-26 | 2009-05-14 | Yonghua Gai | Hydroxyamic analogs as hepatitis c virus serine protease inhibitor |
| BRPI0811020A2 (pt) | 2007-05-03 | 2015-07-21 | Intermune Inc | Composto, composição farmacêutica e métodos de inibição da atividade da protease ns3/ns4, de tratamento da fibrose hepática, de intensificação da função hepática em indivíduo com infecção do vírus da hepatite c e métodos de síntese de compostos, de administração de inibidor da infecção do vírus da hepatite c (hcv) e de distribuição de forma de dosagem oral. |
| PE20090213A1 (es) * | 2007-05-04 | 2009-02-28 | Bristol Myers Squibb Co | Agonistas del receptor acoplado a la proteina g gpr119 [6,5]-biciclicos |
| KR20100027134A (ko) * | 2007-05-10 | 2010-03-10 | 인터뮨, 인크. | Ｃ형 간염 바이러스 복제의 신규 펩티드 억제제 |
| US20090005387A1 (en) * | 2007-06-26 | 2009-01-01 | Deqiang Niu | Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors |
| AU2008271117B2 (en) * | 2007-06-29 | 2013-10-24 | Gilead Sciences, Inc. | Antiviral compounds |
| WO2009014730A1 (en) * | 2007-07-26 | 2009-01-29 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors |
| US20090053175A1 (en) * | 2007-08-24 | 2009-02-26 | Yat Sun Or | Substitute pyrrolidine derivatives |
| US20090060874A1 (en) * | 2007-09-05 | 2009-03-05 | Yao-Ling Qiu | Bicyclic pyrrolidine derivatives |
| JP2010540549A (ja) * | 2007-09-24 | 2010-12-24 | アキリオン ファーマシューティカルズ，インコーポレーテッド | ウイルス複製阻害剤としての尿素含有ペプチド |
| US20090082366A1 (en) * | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched telaprevir |
| BRPI0817881A2 (pt) * | 2007-10-10 | 2015-03-31 | Novartis Ag | Compostos orgânicos e seus usos |
| US20090111757A1 (en) * | 2007-10-25 | 2009-04-30 | Taigen Biotechnology Co., Ltd. | Hcv protease inhibitors |
| US8383583B2 (en) * | 2007-10-26 | 2013-02-26 | Enanta Pharmaceuticals, Inc. | Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors |
| JP2011503231A (ja) * | 2007-11-20 | 2011-01-27 | コンサート ファーマシューティカルズ インコーポレイテッド | Ｈｃｖ感染処置のためのペプチド |
| CA2709032C (en) * | 2007-12-21 | 2016-02-23 | F. Hoffmann-La Roche Ag | Process for the preparation of a macrocycle |
| EP2282762A2 (en) * | 2008-04-15 | 2011-02-16 | Intermune, Inc. | Novel macrocyclic inhibitors of hepatitis c virus replication |
| US20100003217A1 (en) * | 2008-07-02 | 2010-01-07 | Erika Cretton-Scott | Compounds and Pharmaceutical Compositions for the Treatment of Viral Infections |
| CA2732091A1 (en) * | 2008-08-07 | 2010-02-11 | F. Hoffmann-La Roche Ag | Process for the preparation of a macrocycle |
| US7906655B2 (en) * | 2008-08-07 | 2011-03-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| UY32099A (es) * | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
| BRPI0918653A2 (pt) * | 2008-09-17 | 2015-12-01 | Boehringer Ingelheim Int | combinação de inibidor de ns3 protese de hcv com interferon e ribavirina. |
| US8603737B2 (en) * | 2008-09-19 | 2013-12-10 | Celgene Avilomics Research, Inc. | Methods for identifying HCV protease inhibitors |
| US8563505B2 (en) * | 2008-09-29 | 2013-10-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8044087B2 (en) * | 2008-09-29 | 2011-10-25 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US20100080770A1 (en) * | 2008-09-29 | 2010-04-01 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| CA2740728A1 (en) * | 2008-10-15 | 2010-04-22 | Intermune, Inc. | Therapeutic antiviral peptides |
| AU2009316472B2 (en) * | 2008-11-20 | 2015-07-09 | Achillion Pharmaceuticals, Inc. | Cyclic carboxamide compounds and analogues thereof as of Hepatitis C virus |
| US20110064694A1 (en) * | 2009-09-09 | 2011-03-17 | Yale University | Anti-hepatitis c activity of meso-tetrakis-porphyrin analogues |
| US8822700B2 (en) * | 2009-09-11 | 2014-09-02 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8927709B2 (en) * | 2009-09-11 | 2015-01-06 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8759332B2 (en) * | 2009-09-11 | 2014-06-24 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8815928B2 (en) * | 2009-09-11 | 2014-08-26 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8703938B2 (en) * | 2009-09-11 | 2014-04-22 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US9156818B2 (en) * | 2009-09-11 | 2015-10-13 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| SG179566A1 (en) * | 2009-09-15 | 2012-05-30 | Taigen Biotechnology Co Ltd | Hcv protease inhibitors |
| WO2011041551A1 (en) * | 2009-10-01 | 2011-04-07 | Intermune, Inc. | Therapeutic antiviral peptides |
-
2010
- 2010-09-24 WO PCT/US2010/050298 patent/WO2011038293A1/en not_active Ceased
- 2010-09-24 EP EP10819571.0A patent/EP2483290A4/en not_active Withdrawn
- 2010-09-24 AU AU2010298028A patent/AU2010298028A1/en not_active Abandoned
- 2010-09-24 US US12/890,475 patent/US20110081315A1/en not_active Abandoned
- 2010-09-24 CN CN201080053601.9A patent/CN102741270B/zh not_active Expired - Fee Related
- 2010-09-24 MX MX2012003500A patent/MX2012003500A/es not_active Application Discontinuation
- 2010-09-24 EA EA201290128A patent/EA201290128A1/ru unknown
- 2010-09-24 CN CN201510341151.8A patent/CN105001302A/zh active Pending
- 2010-09-24 JP JP2012531086A patent/JP2013505952A/ja not_active Withdrawn
- 2010-09-24 CA CA2775697A patent/CA2775697A1/en not_active Abandoned
- 2010-09-24 PH PH1/2012/500602A patent/PH12012500602A1/en unknown
- 2010-09-24 KR KR1020127010337A patent/KR20130026410A/ko not_active Withdrawn
- 2010-09-24 IN IN2693DEN2012 patent/IN2012DN02693A/en unknown
- 2010-09-28 AR ARP100103512A patent/AR078462A1/es unknown
- 2010-09-28 TW TW099132976A patent/TW201124137A/zh unknown
-
2012
- 2012-03-21 IL IL218766A patent/IL218766A0/en unknown
- 2012-03-27 TN TNP2012000135A patent/TN2012000135A1/en unknown
- 2012-04-26 MA MA34813A patent/MA33720B1/fr unknown
- 2012-04-27 EC ECSP12011845 patent/ECSP12011845A/es unknown
- 2012-04-27 CO CO12069712A patent/CO6531497A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EA201290128A1 (ru) | 2013-01-30 |
| US20110081315A1 (en) | 2011-04-07 |
| CA2775697A1 (en) | 2011-03-31 |
| EP2483290A4 (en) | 2013-05-01 |
| MA33720B1 (fr) | 2012-11-01 |
| AU2010298028A2 (en) | 2012-10-04 |
| JP2013505952A (ja) | 2013-02-21 |
| TN2012000135A1 (en) | 2013-09-19 |
| AR078462A1 (es) | 2011-11-09 |
| CN102741270B (zh) | 2015-07-22 |
| TW201124137A (en) | 2011-07-16 |
| CN105001302A (zh) | 2015-10-28 |
| EP2483290A1 (en) | 2012-08-08 |
| ECSP12011845A (es) | 2012-06-29 |
| IL218766A0 (en) | 2012-06-28 |
| CN102741270A (zh) | 2012-10-17 |
| MX2012003500A (es) | 2012-08-01 |
| KR20130026410A (en) | 2013-03-13 |
| WO2011038293A1 (en) | 2011-03-31 |
| AU2010298028A1 (en) | 2012-04-19 |
| CO6531497A2 (es) | 2012-09-28 |
| PH12012500602A1 (en) | 2017-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2012DN02693A (enExample) | ||
| MX2009011867A (es) | Nuevos inhibidores macrociclicos de la replicacion del virus de hepatitis c. | |
| MX2012003171A (es) | Novedosos inhibidores macrociclicos de la replicacion del virus de hepatitis c. | |
| WO2009142842A3 (en) | Novel macrocyclic inhibitors of hepatitis c virus replication | |
| WO2012087976A3 (en) | Novel inhibitors of hepatitis c virus replication | |
| TN2009000481A1 (en) | Novel peptide inhibitors of hepatitis c virus replication | |
| MX2009008439A (es) | Nuevos inhibidores de la replicacion del virus de hepatitis c. | |
| TW200740851A (en) | Novel macrocyclic inhibitors of hepatitis C virus replication | |
| WO2009134616A8 (en) | Novel inhibitors of hepatitis c virus replication | |
| WO2008005511A3 (en) | Novel inhibitors of hepatitis c virus replication | |
| WO2007047146A3 (en) | Inhibitors of viral replication | |
| UA116616C2 (uk) | Інгібітори hcv серинової протеази, отримані з макроциклічного проліну | |
| TN2012000358A1 (en) | Hepatitis c virus inhibitors | |
| EP2555622A4 (en) | HEPATITIS C-VIRUS HEMMER | |
| MX2012004032A (es) | Compuestos para el tratamiento de hepatitis c. | |
| MY160130A (en) | Hepatitis c virus inhibitors | |
| UA91677C2 (ru) | Макроциклические соединения как ингибиторы вирусной репликации | |
| MX2010010061A (es) | Compuestos para el tratamiento de hepatitis c. | |
| TN2010000468A1 (en) | Novel macrocyclic inhibitors of hepatitis c virus replication | |
| UA95455C2 (ru) | Макроциклические ингибиторы репликации вируса гепатита с | |
| TW200611905A (en) | Macrocyclic compounds as inhibitors of viral replication | |
| CU20090188A7 (es) | Nuevos péptidos inhibidores de la replicación del virus de la hepatitis c | |
| CU20090182A7 (es) | Nuevos inhibidores macrocíclicos de la replicación del virus de hepatitis c |